Trial Profile
Single-Arm, Open-Label, Phase II Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Samotolisib (Primary)
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Sarcoma; Squamous cell cancer
- Focus Therapeutic Use
- 28 Mar 2022 Status changed from active, no longer recruiting to completed.
- 16 Jun 2021 Planned End Date changed from 1 Sep 2021 to 1 Sep 2022.
- 16 Jun 2021 Planned primary completion date changed from 1 Sep 2021 to 1 Sep 2022.